Literature DB >> 17454337

Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.

Myron Liebhaber1, Zeb Dyer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454337     DOI: 10.1080/02770900701209749

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


× No keyword cloud information.
  3 in total

1.  Omalizumab: the evidence for its place in the treatment of allergic asthma.

Authors:  Diarmuid M McNicholl; Liam G Heaney
Journal:  Core Evid       Date:  2008-06

2.  Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.

Authors:  Sarah Denman; Tariq El-Shanaway; Emily Carne; Lisa Devlin; Sinisa Savic
Journal:  Eur J Hosp Pharm       Date:  2019-07-15

3.  Omalizumab: Practical considerations regarding the risk of anaphylaxis.

Authors:  Harold L Kim; Richard Leigh; Allan Becker
Journal:  Allergy Asthma Clin Immunol       Date:  2010-12-03       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.